In a landmark development for cancer research, scientists have unveiled a world-first breath test that could transform how pancreatic cancer is detected; potentially marking the most significant step toward a life-saving breakthrough in 50 years, according to Pancreatic Cancer UK.
Pancreatic cancer remains one of the deadliest forms of the disease, often dubbed the “silent killer” due to its vague early symptoms such as back pain and indigestion. These symptoms frequently lead to late-stage diagnoses, when treatment options are limited and outcomes are poor. Recent audits show that around 62% of patients in England and 65% in Wales are diagnosed at stage four, with 22% of patients in England not surviving beyond 30 days after diagnosis.
Now, scientists at Imperial College London are leading an ambitious clinical trial to change that. Funded by a £1.1 million investment from Pancreatic Cancer UK, the study will test the effectiveness of a simple, non-invasive breath test that could enable earlier, faster, and more accurate diagnosis.
How the test works
The breath test works by detecting unique combinations of volatile organic compounds (VOCs) in a patient’s breath – chemical markers that can reveal the presence of disease. These compounds circulate in the bloodstream and are expelled through the lungs, meaning subtle changes can be identified even when pancreatic cancer is in its earliest stages.
By isolating specific VOC patterns, clinicians can determine whether a person is likely to have pancreatic cancer, with results potentially available to GPs in as little as three days. If successful, the test could be rolled out to GP surgeries within five years, a timeline that offers unprecedented hope for earlier detection.
A major milestone in cancer research
This large-scale trial will involve 6,000 patients with an unknown diagnosis across 40 sites in England, Wales, and Scotland. It follows a smaller study of 700 patients conducted over two years, which produced highly encouraging results.
Diana Jupp, Chief Executive of Pancreatic Cancer UK, described the project as a “moment of real, tangible hope”:
“The breath test has the potential to revolutionise the early detection of pancreatic cancer. While more years of development are still needed before it can reach GP surgeries, this is the first pancreatic cancer breath test to ever reach a national clinical trial of this scale. A real step toward saving lives.”
Professor George Hanna, Head of the Department of Surgery and Cancer at Imperial College London, added:
“If our findings from the initial phase can be validated in this larger population, the test has huge potential to influence clinical practice and cancer referral pathways. We’re now moving quickly to that next stage, which is an incredibly exciting milestone.”
Why this matters
Early detection is critical in improving survival rates for pancreatic cancer. Currently, the disease claims more than 10,000 lives in the UK each year, yet when diagnosed early, treatment such as surgery can be curative. A simple, accurate, and non-invasive breath test could therefore represent a seismic shift in how this devastating disease is managed.
As research progresses, the hope is clear: that within the next decade, patients presenting with non-specific symptoms such as back pain or digestive issues could receive a quick, life-saving test at their GP surgery – turning the tide on one of the toughest challenges in modern oncology.
Back to News + Insights